Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Secondary Prophylactic Hetrombopag for Platinum-Based Chemotherapy-Induced Thrombocytopenia in Lung Cancer
ChiCTR2600130220Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT) (4 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Incidence of grade ≥3 chemotherapy-induced thrombocytopenia (CTIT). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2600130220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130220.